Here are five key points:
1. The expected second quarter revenue is up from the first quarter revenue of $4.7 million.
2. Cash and cash equivalents are about $12.4 million.
3. Net cash used in operating activities from the first half of the year decreased by about $3 million.
4. These expected financial results may change after quarter-end closing adjustments.
5. The FDA asked that Amedica provide 24-month clinical performance data for its Valeo C Interbody with CsC Osteo-Conducting Scaffolding before it will be cleared. Amedica hopes to receive a final response from the FDA in late fourth quarter 2015 or early first quarter 2016.
“I am very pleased with our improved financial discipline this quarter and the progress we’ve made with potential private label and OEM partners,” said Sonny Bal, MD, JD, MBA, chairman and CEO of Amedica.
More articles on devices:
Maryland Brain & Spine adds ‘Pain’ to its name: 5 points
InVivo CEO plans big: 5 key notes on capturing the spinal injury market
DJO Global net sales down 1%: 10 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
